Cost-Effectiveness Analysis of Evolocumab in Adult Patients with Atherosclerotic Cardiovascular Disease in Canada

被引：0
|
作者：
Jean Grégoire
Salimah Champsi
Manon Jobin
Laura Martinez
Michael Urbich
Raina M. Rogoza
机构：
[1] Université de Montréal,Montreal Heart Institute
[2] Amgen Canada Inc.,Health Economics and Market Access, Value Access and Policy
[3] Amgen (Europe) GmbH,Amgen (Europe) GmbH, Global Value and Access
[4] Modeling Center of Excellence,undefined
来源：
Advances in Therapy | 2022年 / 39卷
关键词：
Cost-effectiveness; Cost-utility analysis; Economic evaluation; Canada; Atherosclerotic cardiovascular disease; ASCVD; Evolocumab;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：3262 / 3279
页数：17
相关论文
共 50 条
  • [1] Cost-Effectiveness Analysis of Evolocumab in Adult Patients with Atherosclerotic Cardiovascular Disease in Canada
    Gregoire, Jean
    Champsi, Salimah
    Jobin, Manon
    Martinez, Laura
    Urbich, Michael
    Rogoza, Raina M.
    [J]. ADVANCES IN THERAPY, 2022, 39 (07) : 3262 - 3279
  • [2] Cost-Effectiveness of Evolocumab in Adult Patients with Atherosclerotic Cardiovascular Disease from Chinese Healthcare Perspective
    Wenwen Xie
    Yinyin Song
    Xiaomei Qin
    Pengfei Jin
    [J]. Advances in Therapy, 2023, 40 : 489 - 503
  • [3] Cost-Effectiveness of Evolocumab in Adult Patients with Atherosclerotic Cardiovascular Disease from Chinese Healthcare Perspective
    Xie, Wenwen
    Song, Yinyin
    Qin, Xiaomei
    Jin, Pengfei
    [J]. ADVANCES IN THERAPY, 2023, 40 (02) : 489 - 503
  • [4] Cost-effectiveness of Evolocumab Therapy for Reducing Cardiovascular Events in Patients With Atherosclerotic Cardiovascular Disease
    Fonarow, Gregg C.
    Keech, Anthony C.
    Pedersen, Terje R.
    Giugliano, Robert P.
    Sever, Peter S.
    Lindgren, Peter
    van Hout, Ben
    Villa, Guillermo
    Qian, Yi
    Somaratne, Ransi
    Sabatine, Marc S.
    [J]. JAMA CARDIOLOGY, 2017, 2 (10) : 1069 - 1078
  • [5] Updated Cost-effectiveness Analysis of Evolocumab in Patients With Very High-risk Atherosclerotic Cardiovascular Disease
    Fonarow, Gregg C.
    van Hout, Ben
    Villa, Guillermo
    Arellano, Jorge
    Lindgren, Peter
    [J]. JAMA CARDIOLOGY, 2019, 4 (07) : 691 - 695
  • [6] COST-EFFECTIVENESS OF EVOLOCUMAB IN ATHEROSCLEROTIC CARDIOVASCULAR DISEASE PATIENTS WITH VARYING RISK PROFILES IN SWEDEN
    Lindgren, P.
    Hagstrom, E.
    van Hout, B.
    Villa, G.
    Pemberton-Ross, P.
    Arellano, J.
    Sibartie, M.
    Fonarow, G. C.
    [J]. VALUE IN HEALTH, 2019, 22 : S548 - S548
  • [7] Cost-effectiveness of evolocumab in patients with high atherosclerotic cardiovascular risk in Sweden
    Lindgren, P.
    Hagstrom, E.
    Van Hout, B.
    Villa, G.
    Urbich, M.
    Sandelin, R.
    Svensson, M. Eriksson
    Fonarow, G. C.
    [J]. EUROPEAN HEART JOURNAL, 2019, 40 : 681 - 681
  • [8] Cost-effectiveness of Evolocumab Therapy for Reducing Cardiovascular Events in Patients With Atherosclerotic Cardiovascular Disease (vol 2, pg 1069, 2017)
    Fonarow, G. C.
    Keech, A. C.
    Pedersen, T. R.
    [J]. JAMA CARDIOLOGY, 2017, 2 (10) : 1170 - 1170
  • [9] COST-EFFECTIVENESS OF EVOLOCUMAB IN PATIENTS WITH PRIOR MYOCARDIAL INFARCTION IN CANADA
    Urbich, M.
    Jobin, M.
    Rogoza, R.
    [J]. VALUE IN HEALTH, 2020, 23 : S495 - S495
  • [10] COST-EFFECTIVENESS OF EVOLOCUMAB IN PATIENTS WITH HIGH CARDIOVASCULAR RISK IN SPAIN
    Villa, G.
    Lothgren, M.
    Kutikova, L.
    Lindgren, P.
    Gandra, S. R.
    Fonarow, G. C.
    Sorio, F.
    Masana, L.
    Bayes-Genis, A.
    van Hout, B.
    [J]. VALUE IN HEALTH, 2016, 19 (07) : A651 - A652
12345